Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Receivables - Net (2018 - 2025)

Historic Receivables - Net for Fate Therapeutics (FATE) over the last 9 years, with Q3 2025 value amounting to $682000.0.

  • Fate Therapeutics' Receivables - Net fell 8347.47% to $682000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $682000.0, marking a year-over-year decrease of 8347.47%. This contributed to the annual value of $3.5 million for FY2024, which is 9381.16% up from last year.
  • According to the latest figures from Q3 2025, Fate Therapeutics' Receivables - Net is $682000.0, which was down 8347.47% from $1.4 million recorded in Q2 2025.
  • Over the past 5 years, Fate Therapeutics' Receivables - Net peaked at $38.5 million during Q4 2022, and registered a low of $682000.0 during Q3 2025.
  • Moreover, its 5-year median value for Receivables - Net was $4.1 million (2024), whereas its average is $7.5 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first soared by 50005.82% in 2021, then tumbled by 9525.47% in 2023.
  • Over the past 5 years, Fate Therapeutics' Receivables - Net (Quarter) stood at $8.7 million in 2021, then surged by 343.52% to $38.5 million in 2022, then tumbled by 95.25% to $1.8 million in 2023, then skyrocketed by 93.81% to $3.5 million in 2024, then crashed by 80.73% to $682000.0 in 2025.
  • Its Receivables - Net stands at $682000.0 for Q3 2025, versus $1.4 million for Q2 2025 and $2.4 million for Q1 2025.